Literature DB >> 9886355

Effect of omega-conotoxin GVIA and omega-agatoxin IVA on the capsaicin-sensitive calcitonin gene-related peptide release and autoregulatory vasodilation in rat pial arteries.

K W Hong1, C D Kim, B Y Rhim, W S Lee.   

Abstract

This study assesses the effect of neuronal voltage-sensitive Ca2+ channel blockers, omega-conotoxin GVIA (CTX), and omega-agatoxin IVA (AgTX) on the vasodilation and release of calcitonin gene-related peptide (CGRP), both of which were induced by either application of capsaicin or acute stepwise hypotension. Changes in pial arterial diameter were determined directly through a closed cranial window. The vasodilation of pial artery induced by either CGRP (0.1 micromol/L) or capsaicin (0.3 micromol/L) was significantly inhibited by CGRP(8-37) (0.1 micromol/L) (P < 0.05 and P < 0.05, respectively). The autoregulatory vasodilation to acute stepwise hypotension was severely attenuated by pretreatment with either CTX or AgTX. When the hypotension was kept for 2, 4, and 10 minutes, the releasable CGRP-like immunoreactivity (CGRP-LI) level (vehicle, 13.4+/-1.5 fmol/mm2/30 min) by 10 micromol/L capsaicin from the isolated pial arteries was significantly reduced in the 4- and 10-minute hypotension groups (11.3+/-1.2 fmol/mm2/30 min, P < 0.05, and 11.1+/-1.5 fmol/mm2/30 min, P < 0.05, respectively), but not in 2-min group. Moreover, the CGRP-LI level released by 10 micromol/L capsaicin (13.7+/-0.9 fmol/mm2/30 min) also was significantly depressed by pretreatment with 1 micromol/L CTX to 10.4+/-1.0 fmol/mm2/30 min (P < 0.01) and with 0.1 micromol/L AgTX to 8.7(1.7 fmol/mm2/30 min (P < 0.001), as well as by pretreatment with 10 micro-mol/L capsaicin (6.0+/-1.6 fmol/ mm2/30 min, P < 0.001). These results suggest that the neuronal N- and P-type voltage-sensitive Ca2+ channels are implicated in the release of CGRP from capsaicin-sensitive perivascular sensory nerves in response to acute hypotension, and that the released CGRP may contribute to the autoregulatory vasodilation in the cerebral microcirculation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886355     DOI: 10.1097/00004647-199901000-00006

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  6 in total

1.  Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons.

Authors:  Ilya Buldyrev; Nathan M Tanner; Hui-ya Hsieh; Emily G Dodd; Loi T Nguyen; Agnieszka Balkowiec
Journal:  J Neurochem       Date:  2006-10-25       Impact factor: 5.372

2.  Effects of familial hemiplegic migraine type 1 mutation T666M on voltage-gated calcium channel activities in trigeminal ganglion neurons.

Authors:  Jin Tao; Ping Liu; Zheman Xiao; Hucheng Zhao; Benjamin R Gerber; Yu-Qing Cao
Journal:  J Neurophysiol       Date:  2011-12-21       Impact factor: 2.714

Review 3.  Insights into migraine mechanisms and CaV2.1 calcium channel function from mouse models of familial hemiplegic migraine.

Authors:  Daniela Pietrobon
Journal:  J Physiol       Date:  2010-03-01       Impact factor: 5.182

4.  Trigeminal ganglion neuron subtype-specific alterations of Ca(V)2.1 calcium current and excitability in a Cacna1a mouse model of migraine.

Authors:  B Fioretti; L Catacuzzeno; L Sforna; M B Gerke-Duncan; A M J M van den Maagdenberg; F Franciolini; M Connor; D Pietrobon
Journal:  J Physiol       Date:  2011-10-17       Impact factor: 5.182

5.  Antimigraine drug, zolmitriptan, inhibits high-voltage activated calcium currents in a population of acutely dissociated rat trigeminal sensory neurons.

Authors:  Tomoko Morikawa; Yoshiyasu Matsuzawa; Koshi Makita; Yoshifumi Katayama
Journal:  Mol Pain       Date:  2006-03-20       Impact factor: 3.395

6.  Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling.

Authors:  Yan Xiao; Judith A Richter; Joyce H Hurley
Journal:  Mol Pain       Date:  2008-04-16       Impact factor: 3.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.